(LIH-fih-LOO-sel)
Lifileucel is a type of tumor-infiltrating lymphocyte (TIL) therapy. TIL therapy involves removing immune cells from a patient’s tumor and testing them in the lab to find out which ones best recognize the tumor cells. The selected immune cells are then grown in large numbers in the lab and given back to the patient to help their immune system kill the tumor cells.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Lifileucel is approved to treat:
- Melanoma. It is used in adults whose cancer has spread to other parts of the body or cannot be removed by surgery. It is used when the cancer did not respond or stopped responding to an antibody that blocks PD-1 and, if the cancer has an abnormal BRAF gene, a BRAF inhibitor with or without a MEK inhibitor.
Lifileucel is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.
Lifileucel is also being studied in the treatment of other types of cancer.
More About Lifileucel
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
Research Results and Related Resources
First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma
Clinical Trials Accepting Patients
Find Clinical Trials for Lifileucel – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
